PRAXIS PRECISION MEDICINES I (PRAX)
US74006W2070 - Common Stock
PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024
PRAX stock results show that Praxis Precision Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Praxis Precision Medicine (NASDAQ:PRAX) just reported results for the first qua...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively ...
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor...
Praxis Precision Medicines to Participate in Upcoming April Conferences
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big
The company said 100% of patients who received the high dose responded to its drug.
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a...
Praxis Precision Medicines to Host PRAX-628 Program Update
Praxis Precision Medicines to Host PRAX-628 Program Update
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr....
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Beats Revenue for Q4 2023
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Praxis Precision Medicine (NASDAQ:PRAX) just reported results for the fourth qu...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential...
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Praxis Precision Medicines falls after pricing of $150M equity offering (NASDAQ:PRAX)
Praxis Precision Medicines priced its public offering, raising $150M with a mixture of common shares and pre-funded warrants. Shares dropped 5% premarket.